Study to Evaluate the Efficacy of Adalimumab in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

TNF-Blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints: Randomized, Double Blind, Placebo-Controlled Cross-Over Study to Evaluate the Efficacy of Adalimumab 40 mg SC Every Other Week in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00296894

Enrollment

Registered

2006-02-27

Start date

2006-05-31

Completion date

2009-02-28

Last updated

2009-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive Osteo-Arthritis

Brief summary

Patients will be randomized into two groups (1/1) during one year: * 40 mg adalimumab subcutaneously (sc) every other week * placebo The effect on x-rays and clinical parameters will be evaluated.

Interventions

DRUGAdalimumab (40 mg sc every other week)

Adalimumab (40 mg sc every other week)

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clear erosive image on x-ray of at least one interphalangeal finger joint

Design outcomes

Primary

Measure	Time frame
Evaluation of x-rays	—
Evaluation of clinical parameters (pain, daily functioning, etc.)	—

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026